Francke Stephan
Curr Opin Investig Drugs. 2002 Nov;3(11):1624-8.
TAK-677 is a beta3-adrenergic agonist under development by Dainippon and Takeda for the potential treatment of non-insulin dependent diabetes and obesity. In March 2001, Takeda initiated a phase II trial in the US for Type II diabetes [411811], [416686], [423455]. By December 2001, the compound was also in phase II trials for obesity in the US, and Dainippon was conducting phase II studies in Japan for diabetes [458750].
TAK-677是由大日本制药和武田制药正在研发的一种β3-肾上腺素能激动剂，用于潜在治疗非胰岛素依赖型糖尿病和肥胖症。2001年3月，武田制药在美国启动了一项针对II型糖尿病的II期试验[411811]、[416686]、[423455]。到2001年12月，该化合物在美国也进入了针对肥胖症的II期试验，大日本制药在日本正在进行针对糖尿病的II期研究[458750]。
